Corrigendum to IgA nephropathy: An overview of the clinical trials (Kidney Med. 2025;7:101078)

Authors

Zohreh Gholizadeh Ghozloujeh, Department of Medicine, Division of Nephrology, Loma Linda University, Loma Linda, CA.
Haresh Selvaskandan, John Walls Renal Unit, University Hospitals Leicester NHS Trust, Leicester, UK.
Nasim Wiegley, Department of Medicine, Division of Nephrology, University of California Davis School of Medicine, Division of Nephrology, Sacramento, CA.
Edgar Lerma, Advocate Health - MidwestFollow
Jorge Gaytan, Division of Medicine, Department of Internal Medicine and Nephrology, High Specialty Medical Unit No. 71, Mexican Social Security Institute (IMSS), Torreon, Mexico.
Alejandro Garcia-Rivera, Department of Nephrology, Hospital General Regional 46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.
Amir Abdipour, Department of Medicine, Division of Nephrology, Loma Linda University, Loma Linda, CA.
Sayna Norouzi, Department of Medicine, Division of Nephrology, Loma Linda University, Loma Linda, CA.

Recommended Citation

Ghozloujeh ZG, Selvaskandan H, Wiegley N, et al. Corrigendum to IgA Nephropathy: An Overview of the Clinical Trials (Kidney Med. 2025;7:101078). Kidney Med. 2025;7(12):101132. Published 2025 Oct 1. doi:10.1016/j.xkme.2025.101132

Affiliations

Advocate Christ Medical Center

Abstract

This corrects the article "IgA Nephropathy: An Overview of the Clinical Trials", 101078.

Document Type

Article

PubMed ID

41245263